-
Je něco špatně v tomto záznamu ?
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations
C. Porta, A. Bamias, R. Zakopoulou, ZW. Myint, N. Cavasin, R. Iacovelli, M. Pichler, J. Kopecky, J. Kucharz, M. Rizzo, L. Galli, T. Büttner, U. DE Giorgi, R. Kanesvaran, O. Fiala, E. Grande, PA. Zucali, RM. Kopp, G. Fornarini, MT. Bourlon, S....
Jazyk angličtina Země Itálie
Typ dokumentu pozorovací studie, multicentrická studie, časopisecké články
- MeSH
- cytoredukční chirurgie MeSH
- karcinom z renálních buněk * chirurgie patologie MeSH
- lidé MeSH
- nádory ledvin * chirurgie patologie MeSH
- nefrektomie MeSH
- retrospektivní studie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- pozorovací studie MeSH
BACKGROUND: The upfront treatment of metastatic renal cell carcinoma (mRCC) has been revolutionized by the introduction of immune-based combinations. The role of cytoreductive nephrectomy (CN) in these patients is still debated. The ARON-1 study (NCT05287464) was designed to globally analyze real-world data of mRCC patients receiving first-line immuno-oncology combinations. This sub-analysis is focused on the role of upfront or delayed partial or radical CN in three geographical areas (Western Europe, Eastern Europe, America/Asia). METHODS: We conducted a multicenter retrospective observational study in mRCC patients treated with first-line immune combinations from 55 centers in 19 countries. From 1152 patients in the ARON-1 dataset, we selected 651 patients with de novo mRCC. 255 patients (39%) had undergone CN, partial in 14% and radical in 86% of cases; 396 patients (61%) received first-line immune-combinations without previous nephrectomy. RESULTS: Median overall survival (OS) from the diagnosis of de novo mRCC was 41.6 months and not reached (NR) in the CN subgroup and 24.0 months in the no CN subgroup, respectively (P<0.001). Median OS from the start of first-line therapy was NR in patients who underwent CN and 22.4 months in the no CN subgroup (P<0.001). Patients who underwent CN reported longer OS compared to no CN in all the three geographical areas. CONCLUSIONS: No significant differences in terms of patients' outcome seem to clearly emerge, even if the rate CN and the choice of the type of first-line immune-based combination varies across the different Cancer Centers participating in the ARON-1 project.
Albert Einstein Israelite Hospital São Paulo Brazil
Chair of Oncology Interdisciplinary Department of Medicine Aldo Moro University of Bari Bari Italy
Clinic of Urology Lübeck Germany
Clinical Oncology Sociedad de Oncología y Hematología del Cesar Valledupar Colombia
Department of Biomedical Sciences Humanitas University Pieve Emanuele Milan Italy
Department of Internal Medicine and Medical Specialties University of Genoa Genoa Italy
Department of Internal Medicine Hematology Oncology Ochsner Medical Center New Orleans LA USA
Department of Medical Oncology Army Hospital Research and Referral New Delhi India
Department of Medical Oncology Hospital Ramón y Cajal Madrid Spain
Department of Medical Oncology IRCCS Istituto Nazionale Tumori Foundation Milan Italy
Department of Medical Oncology Jolimont Hospital Center Haine Saint Paul Belgium
Department of Medical Oncology La Paz University Hospital Madrid Spain
Department of Medical Oncology Maggiore della Carità University Hospital Novara Italy
Department of Medical Oncology MD Anderson Cancer Center of Madrid Madrid Spain
Department of Medical Oncology Ospedale Maggiore of Cremona Cremona Italy
Department of Medical Oncology San Paolo Hospital Savona Italy
Department of Medical Oncology Tawam Hospital Al Ain United Arab Emirates
Department of Medical Oncology1 IRCCS Regina Elena National Cancer Institute Rome Italy
Department of Oncology and Hematology Santa Lucia Hospital Brasília Brazil
Department of Oncology Candiolo Cancer Institute IRCCS FPO Candiolo Turin Italy
Department of Oncology IRCCS Humanitas Research Hospital Rozzano Milan Italy
Department of Oncology San Camillo Forlanini Hospital Rome Italy
Department of Oncology Tays Cancer Center Tampere University Hospital Tampere Finland
Department of Urologic Oncology Champalimaud Clinical Center Lisbon Portugal
Department of Urology Medical University of Innsbruck Innsbruck Austria
Department of Urology University Hospital Bonn UKB Bonn Germany
Division of Medical Oncology A O U Consorziale Policlinico di Bari Bari Italy
Division of Medical Oncology National Cancer Center Singapore Singapore
Division of Oncology Department of Internal Medicine Medical University of Graz Graz Austria
Division of Oncology Institute for Cancer Research and Treatment Asl Cn2 Alba Bra Alba Cuneo Italy
IRCCS San Martino University Hospital Genoa Italy
Latin American Cooperative Oncology Group LACOG Porto Alegre Brazil
Markey Cancer Center University of Kentucky Lexington KY USA
Medical Oncology IRCCS Azienda Ospedaliero Universitaria di Bologna Bologna Italy
Oncologia Medica IRCCS A Gemelli University Polyclinic Foundation Rome Italy
Oncology Unit2 University Hospital of Pisa Pisa Italy
Oncology3 Unit Department of Oncology Istituto Oncologico Veneto IOV IRCCS Padua Italy
Unit of Medical Oncology A Murri Hospital Fermo Italy
Unit of Medical Oncology Gemelli Molise Hospital Sacred Heart Catholic University Campobasso Italy
Unit of Medical Oncology Pugliese Ciaccio Hospital Catanzaro Italy
Unit of Medical Oncology Santa Chiara Hospital Trento Italy
Unit of Medical Oncology University Hospital of Cagliari Cagliari Italy
Unit of Oncology A R N A S Civico Palermo Italy
Unit of Oncology Azienda Ospedaliera di Rilievo Nazionale Cardarelli of Naples Naples Italy
Unit of Oncology Azienda Ospedaliera Ospedali Riuniti Marche Nord Pesaro Italy
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23016644
- 003
- CZ-PrNML
- 005
- 20231026105645.0
- 007
- ta
- 008
- 231013s2023 it f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.23736/S2724-6051.23.05369-7 $2 doi
- 035 __
- $a (PubMed)37530662
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a it
- 100 1_
- $a Porta, Camillo $u Division of Medical Oncology, A.O.U. Consorziale Policlinico di Bari, Bari, Italy $u Chair of Oncology, Interdisciplinary Department of Medicine, Aldo Moro University of Bari, Bari, Italy
- 245 10
- $a Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations / $c C. Porta, A. Bamias, R. Zakopoulou, ZW. Myint, N. Cavasin, R. Iacovelli, M. Pichler, J. Kopecky, J. Kucharz, M. Rizzo, L. Galli, T. Büttner, U. DE Giorgi, R. Kanesvaran, O. Fiala, E. Grande, PA. Zucali, RM. Kopp, G. Fornarini, MT. Bourlon, S. Scagliarini, J. Molina-Cerrillo, G. Aurilio, MR. Matrana, R. Pichler, C. Cattrini, T. Büchler, F. Massari, V. Mollica, E. Seront, F. Calabrò, A. Pinto, R. Berardi, A. Zgura, G. Mammone, J. Ansari, F. Atzori, R. Chiari, O. Caffo, G. Procopio, K. Sunela, M. Bassanelli, C. Ortega, F. Grillone, J. Landmesser, S. Merler, C. Messina, Z. Küronya, A. Mosca, D. Bhuva, D. Santini, N. Vau, F. Morelli, L. Incorvaia, SE. Rebuzzi, G. Roviello, A. Soares, IO. Zabalza, A. Rizzo, R. Bisonni, F. Pierantoni, G. Sorgentoni, FS. Monteiro, N. Battelli, S. Buti, M. Santoni
- 520 9_
- $a BACKGROUND: The upfront treatment of metastatic renal cell carcinoma (mRCC) has been revolutionized by the introduction of immune-based combinations. The role of cytoreductive nephrectomy (CN) in these patients is still debated. The ARON-1 study (NCT05287464) was designed to globally analyze real-world data of mRCC patients receiving first-line immuno-oncology combinations. This sub-analysis is focused on the role of upfront or delayed partial or radical CN in three geographical areas (Western Europe, Eastern Europe, America/Asia). METHODS: We conducted a multicenter retrospective observational study in mRCC patients treated with first-line immune combinations from 55 centers in 19 countries. From 1152 patients in the ARON-1 dataset, we selected 651 patients with de novo mRCC. 255 patients (39%) had undergone CN, partial in 14% and radical in 86% of cases; 396 patients (61%) received first-line immune-combinations without previous nephrectomy. RESULTS: Median overall survival (OS) from the diagnosis of de novo mRCC was 41.6 months and not reached (NR) in the CN subgroup and 24.0 months in the no CN subgroup, respectively (P<0.001). Median OS from the start of first-line therapy was NR in patients who underwent CN and 22.4 months in the no CN subgroup (P<0.001). Patients who underwent CN reported longer OS compared to no CN in all the three geographical areas. CONCLUSIONS: No significant differences in terms of patients' outcome seem to clearly emerge, even if the rate CN and the choice of the type of first-line immune-based combination varies across the different Cancer Centers participating in the ARON-1 project.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a karcinom z renálních buněk $x chirurgie $x patologie $7 D002292
- 650 12
- $a nádory ledvin $x chirurgie $x patologie $7 D007680
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a nefrektomie $7 D009392
- 650 _2
- $a cytoredukční chirurgie $7 D065426
- 655 _2
- $a pozorovací studie $7 D064888
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Bamias, Aristotelis $u Second Propedeutic Department of Internal Medicine, ATTIKON University Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
- 700 1_
- $a Zakopoulou, Roubini $u Second Propedeutic Department of Internal Medicine, ATTIKON University Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
- 700 1_
- $a Myint, Zin W $u Markey Cancer Center, University of Kentucky, Lexington, KY, USA
- 700 1_
- $a Cavasin, Nicolò $u Oncology3 Unit, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy
- 700 1_
- $a Iacovelli, Roberto $u Oncologia Medica, IRCCS A. Gemelli University Polyclinic Foundation, Rome, Italy
- 700 1_
- $a Pichler, Martin $u Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
- 700 1_
- $a Kopecky, Jindrich $u Department of Clinical Oncology and Radiotherapy, University Hospital of Hradec Kralove, Hradec Kralove, Czech Republic
- 700 1_
- $a Kucharz, Jakub $u Department of Uro-Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
- 700 1_
- $a Rizzo, Mimma $u Division of Medical Oncology, A.O.U. Consorziale Policlinico di Bari, Bari, Italy
- 700 1_
- $a Galli, Luca $u Oncology Unit2, University Hospital of Pisa, Pisa, Italy
- 700 1_
- $a Büttner, Thomas $u Department of Urology, University Hospital Bonn UKB, Bonn, Germany
- 700 1_
- $a DE Giorgi, Ugo $u Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Forlì-Cesena, Italy
- 700 1_
- $a Kanesvaran, Ravindran $u Division of Medical Oncology, National Cancer Center Singapore, Singapore
- 700 1_
- $a Fiala, Ondřej $u Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic
- 700 1_
- $a Grande, Enrique $u Department of Medical Oncology, MD Anderson Cancer Center of Madrid, Madrid, Spain
- 700 1_
- $a Zucali, Paolo A $u Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy $u Department of Oncology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
- 700 1_
- $a Kopp, Ray M $u Clinical Oncology, Sociedad de Oncología y Hematología del Cesar, Valledupar, Colombia
- 700 1_
- $a Fornarini, Giuseppe $u IRCCS San Martino University Hospital Genoa, Italy
- 700 1_
- $a Bourlon, Maria T $u Department of Hematology and Oncology, Salvador Zubirán National Institute of Medical and Nutritional Sciences, Mexico City, Mexico
- 700 1_
- $a Scagliarini, Sarah $u Unit of Oncology, Azienda Ospedaliera di Rilievo Nazionale Cardarelli of Naples, Naples, Italy
- 700 1_
- $a Molina-Cerrillo, Javier $u Department of Medical Oncology, Hospital Ramón y Cajal, Madrid, Spain
- 700 1_
- $a Aurilio, Gaetano $u Medical Oncology Division of Urogenital and Head and Neck Tumors, European Institute of Oncology IEO IRCCS, Milan, Italy
- 700 1_
- $a Matrana, Marc R $u Department of Internal Medicine, Hematology/Oncology, Ochsner Medical Center, New Orleans, LA, USA
- 700 1_
- $a Pichler, Renate $u Department of Urology, Medical University of Innsbruck, Innsbruck, Austria
- 700 1_
- $a Cattrini, Carlo $u Department of Medical Oncology, Maggiore della Carità University Hospital, Novara, Italy
- 700 1_
- $a Büchler, Tomáš $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, Prague, Czech Republic $u Department of Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
- 700 1_
- $a Massari, Francesco $u Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy - francesco.massari@aosp.bo.it
- 700 1_
- $a Mollica, Veronica $u Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
- 700 1_
- $a Seront, Emmanuel $u Department of Medical Oncology, Jolimont Hospital Center, Haine Saint Paul, Belgium
- 700 1_
- $a Calabrò, Fabio $u Department of Oncology, San Camillo Forlanini Hospital, Rome, Italy
- 700 1_
- $a Pinto, Alvaro $u Department of Medical Oncology, La Paz University Hospital, Madrid, Spain
- 700 1_
- $a Berardi, Rossana $u Department of Medical Oncology, AOU Ospedali Riuniti delle Marche, Marche Polytechnic University, Ancona, Italy
- 700 1_
- $a Zgura, Anca $u Department of Oncology-Radiotherapy, Prof. Dr. Alexandru Trestioreanu Institute of Oncology, University of Medicine and Pharmacy, Bucharest, Romania
- 700 1_
- $a Mammone, Giulia $u Department of Radiological, Oncological and Anatomo-Pathological Science, Sapienza University of Rome, Rome, Italy
- 700 1_
- $a Ansari, Jawaher $u Department of Medical Oncology, Tawam Hospital, Al Ain, United Arab Emirates
- 700 1_
- $a Atzori, Francesco $u Unit of Medical Oncology, University Hospital of Cagliari, Cagliari, Italy
- 700 1_
- $a Chiari, Rita $u Unit of Oncology, Azienda Ospedaliera Ospedali Riuniti Marche Nord, Pesaro, Italy
- 700 1_
- $a Caffo, Orazio $u Unit of Medical Oncology, Santa Chiara Hospital, Trento, Italy
- 700 1_
- $a Procopio, Giuseppe $u Department of Medical Oncology, IRCCS Istituto Nazionale Tumori Foundation, Milan, Italy $u Department of Medical Oncology, Ospedale Maggiore of Cremona, Cremona, Italy
- 700 1_
- $a Sunela, Kaisa $u Department of Oncology, Tays Cancer Center, Tampere University Hospital, Tampere, Finland
- 700 1_
- $a Bassanelli, Maria $u Department of Medical Oncology1, IRCCS Regina Elena National Cancer Institute, Rome, Italy
- 700 1_
- $a Ortega, Cinzia $u Division of Oncology, Institute for Cancer Research and Treatment, Asl Cn2 Alba-Bra, Alba, Cuneo, Italy
- 700 1_
- $a Grillone, Francesco $u Unit of Medical Oncology, Pugliese-Ciaccio Hospital, Catanzaro, Italy
- 700 1_
- $a Landmesser, Johannes $u Clinic of Urology, Lübeck, Germany
- 700 1_
- $a Merler, Sara $u Section of Oncology, Department of Medicine, University of Verona School of Medicine, Verona University Hospital, Verona, Italy
- 700 1_
- $a Messina, Carlo $u Unit of Oncology, A.R.N.A.S. Civico, Palermo, Italy
- 700 1_
- $a Küronya, Zsófia $u Department of Genitourinary Medical Oncology and Clinical Pharmacology, National Institute of Oncology, Budapest, Hungary
- 700 1_
- $a Mosca, Alessandra $u Department of Oncology, Candiolo Cancer Institute, IRCCS-FPO, Candiolo, Turin, Italy
- 700 1_
- $a Bhuva, Dipen $u Department of Medical Oncology, Army Hospital Research and Referral, New Delhi, India
- 700 1_
- $a Santini, Daniele $u Department of Radiological, Oncological and Pathological Sciences, Umberto I Polyclinic Hospital, Sapienza University, Rome, Italy
- 700 1_
- $a Vau, Nuno $u Department of Urologic Oncology, Champalimaud Clinical Center, Lisbon, Portugal
- 700 1_
- $a Morelli, Franco $u Unit of Medical Oncology, Gemelli Molise Hospital, Sacred Heart Catholic University, Campobasso, Italy
- 700 1_
- $a Incorvaia, Lorena $u Section of Medical Oncology, Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy
- 700 1_
- $a Rebuzzi, Sara E $u Department of Medical Oncology, San Paolo Hospital, Savona, Italy $u Department of Internal Medicine and Medical Specialties (Di.M.I.), University of Genoa, Genoa, Italy
- 700 1_
- $a Roviello, Giandomenico $u Section of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence, Italy
- 700 1_
- $a Soares, Andrey $u Latin American Cooperative Oncology Group - LACOG, Porto Alegre, Brazil $u Albert Einstein Israelite Hospital, São Paulo, Brazil
- 700 1_
- $a Zabalza, Ignacio O $u Department of Medical Oncology, MD Anderson Cancer Center of Madrid, Madrid, Spain
- 700 1_
- $a Rizzo, Alessandro $u Struttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico Don Tonino Bello, IRCCS Istituto Tumori Giovanni Paolo II IRCCS Cancer Institute, Bari, Italy
- 700 1_
- $a Bisonni, Renato $u Unit of Medical Oncology, A. Murri Hospital, Fermo, Italy
- 700 1_
- $a Pierantoni, Francesco $u Oncology3 Unit, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy
- 700 1_
- $a Sorgentoni, Giulia $u Unit of Oncology, Hospital of Macerata, Macerata, Italy
- 700 1_
- $a Monteiro, Fernando S $u Latin American Cooperative Oncology Group - LACOG, Porto Alegre, Brazil $u Department of Oncology and Hematology, Santa Lucia Hospital, Brasília, Brazil
- 700 1_
- $a Battelli, Nicola $u Unit of Oncology, Hospital of Macerata, Macerata, Italy
- 700 1_
- $a Buti, Sebastiano $u Unit of Medical Oncology, Department of Medicine and Surgery, University Hospital of Parma, University of Parma, Parma, Italy
- 700 1_
- $a Santoni, Matteo $u Unit of Oncology, Hospital of Macerata, Macerata, Italy
- 773 0_
- $w MED00208300 $t Minerva urology and nephrology $x 2724-6442 $g Roč. 75, č. 4 (2023), s. 460-470
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37530662 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20231013 $b ABA008
- 991 __
- $a 20231026105639 $b ABA008
- 999 __
- $a ok $b bmc $g 2000266 $s 1203006
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 75 $c 4 $d 460-470 $e - $i 2724-6442 $m Minerva urology and nephrology $n Minerva Urol Nephrol $x MED00208300
- LZP __
- $a Pubmed-20231013
